source
- Atara and Pierre Fabre's T-cell therapy gets new chance for FDA approval after twice rejectedAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have received notice from the U.S. FDA that it will reconsider a previously rejected T-cell therapy. The therapy, which had been turned down…
- Astellas reports promising early results for stem cell eye therapy ASP7317 in age-related diseaseAstellas announced data from an early-stage trial of ASP7317, a stem cell-derived therapy aimed at an age-related eye condition. The study showed encouraging signs of efficacy and safety in most p…